Immune-Competent Cell Manifestations in Psoriatic Arthritis Achilles Tendons
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorOdense University Hospital
About this trial
Tendon pathologies (enthesitis) are a characteristic component of psoriatic arthritis (PsA), and are observed in 35% to 50% of PsA patients. The Achilles tendon is one of the most commonly affected sites. This condition often causes great morbidity and loss of quality of life, and response only suboptimal to current intervention strategies. One of the main obstacles for the development of effective treatment methods is that the disease mechanisms remain poorly understood. To our knowledge, no one has yet ascertained the presence and function of immune-competent cells and inflammatory markers in tendons tissue from PsA patients suffering from Achilles enthesitis.
Eligibility criteria
Qualifiers
Fulfilling the CASPAR criteria
Insertional Achilles tendon pain
Ultrasonic findings of inflammatory disease at the painful Achilles tendon insertion (= enthesitis) defined as abnormally hypoechoic (loss of normal fibrillar architecture) and/or thickened tendon at its bony attachment, seen in two perpendicular planes that may exhibit a Doppler signal or bony changes, including enthesophytes, and erosions.
Disqualifiers
Other inflammatory rheumatic diseases than PsA
Ultrasonic signs of complete rupture of the Achilles tendon
Not wishing to participate or not suited for project evaluation
Trial design
Treatments tested in this trial
- Tendon biopsy procedure
Treatment groups
No treatment groups listed
Sponsors and collaborators
Odense University Hospital
Lead sponsor
University of Southern Denmark
Collaborator
Odense Patient Data Explorative Network
Collaborator
The Danish Rheumatism Association
Collaborator
The Psoriasis Association, Denmark
Collaborator
Source ClinicalTrials.gov